GH1 and central nervous system neoplasm: Nevertheless, using the same multi-center cohort of CCS and reporting specifically on the risk of subsequent central nervous system neoplasms after a longer period of follow-up, Patterson et al. recently reported an adjusted rate ratio of meningioma and gliomas in GH treated survivors of CNS tumors when compared to CNS tumor survivors who were not treated with GH of 1.0 (95% CI 0.6–1.8, p = 0.94), thus indicating negligible differences between the two groups in regards to this particular risk (32).